Robert Gould compensation by year
Fulcrum Therapeutics Summary Compensation Table · all 6 fiscal years held| Component | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|
| Salary | $442,900 | $478,195 | $535,000 | $167,681 | $0 | $300,000 |
| Bonus | $203,734 | $300,000 | $240,750 | — | $0 | $0 |
| Stock awards | $207,000 | $0 | $0 | $0 | $0 | $0 |
| Option awards | $0 | $3,111,158 | $2,240,600 | $2,174,058 | $73,342 | $76,404 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $0 | $0 | $0 | $0 | $45,000 | $48,097 |
| Total | $853,634 | $3,889,353 | $3,016,350 | $2,341,739 | $118,342 | $424,501 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Fulcrum Therapeutics, Inc. DEF 14A filed April 19, 2024, accession 0001193125-24-102863, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Fulcrum Therapeutics, Inc. filed document, accession 0001193125-24-102863. Every figure is read from that document and cited to the page and table it appears in. Filed April 19, 2024.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 12,500 | — | $16.87 |
| Option | 30,000 | — | $3.16 |
| Option | 84,184 | — | $11.33 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Fulcrum Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
7 Form 4 lines since the FY2023 proxy (filed April 19, 2024)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-30 | Grant or award derivative | — | 32,000 | $0.00 | 32,000 |
| 2026-02-02 | Sale | — | 15,000 | $10.72 | 454,864 |
| 2026-01-02 | Sale | — | 15,000 | $10.87 | 469,864 |
| 2026-01-02 | Sale | — | 15,000 | $11.87 | 469,864 |
| 2025-11-19 | Sale | — | 15,000 | $11.03 | 484,864 |
| 2025-06-26 | Grant or award derivative | — | 36,000 | $0.00 | 36,000 |
| 2024-06-17 | Grant or award derivative | — | 30,000 | $0.00 | 30,000 |
The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Fulcrum Therapeutics’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Alex Sapir | President and Chief Executive Officer | $6,990,596 |
| Curtis Oltmans | Chief Legal Officer | $2,319,661 |
| Mel Hayes | Executive Vice President, Patient Affairs | $2,192,854 |
| Alan Musso | Chief Financial Officer | $1,879,833 |
| Bryan Stuart | Former President and Chief Executive Officer | $1,869,696 |
| Robert Gould · this page | Former Interim President and Chief Executive Officer | $424,501 |
Board service
Fulcrum Therapeutics board · FY2022–FY2025| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $50,000 | — | $219,406 | — | $269,406 |
| FY2024 | $50,000 | $0 | $167,559 | $0 | $217,559 |
| FY2023 | — | — | — | — | — |
| FY2022 | $45,000 | — | $73,342 | — | $118,342 |
Each year as the company reported it in Fulcrum Therapeutics's director compensation table. Totals are the company's own disclosed totals.
How this board is paid
Company policy: Fulcrum Therapeutics pays directors a $40,000 cash retainer. As stated in Fulcrum Therapeutics's FY2025 proxy.
Committees
Science and Technology (Chair)
The full Fulcrum Therapeutics compensation record
free company briefThis page is one person within Fulcrum Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Fulcrum Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.